Professor Proby graduated in Medicine from Oxford University and The Middlesex Hospital, London, in 1982. She entered Dermatology in 1987 (St Georges Hospital, London), becoming a clinical research fellow in 1989 with Professor Irene Leigh (The Royal London Hospital). She undertook clinical training in photobiology (St John’s Institute of Dermatology 1992-1994), before rejoining Barts and the London School of Medicine and Dentistry (BLSMD) as a Senior Lecturer in Dermatology in 1994. Professor Proby was Senior Lecturer at BLSMD establishing a longitudinal cohort study of skin cancer in organ transplant recipients and leading the clinical programme for the Cancer Research UK Skin Tumour Laboratory. She was awarded FRCP in 2004 and then moved to Dundee as Clinical Reader in 2007. Since her move to Dundee, she has been appointed Secretary of the Scottish Dermatological Society Skin Cancer Group, President of the British Society for Skin Care in Immunosuppressed Individuals, Chair of the Scottish Intercollegiate Guidelines Network for cutaneous Squamous Cell Carcinoma (SIGN SCC), member of the NCRI non-melanoma skin cancer clinical studies group, member of the British Association of Dermatologists Skin Cancer Prevention Committee, Board member of Skin Care in Organ transplant Patients in Europe (SCOPE) and UK representative on the International Transplant Skin Cancer Collaboration (ITSCC).

South AP, Purdie KJ, Watt SA, Haldenby S, den Breems NY, Dimon M, Arron ST, Kluk MJ, Aster JC, McHugh A, Xue DJ, Dayal JH, Robinson KS, Rizvi SM, Proby CM, Harwood CA, Leigh IM. NOTCH1 Mutations Occur Early during Cutaneous Squamous Cell Carcinogenesis. J Invest Dermatol. 2014 Mar 24. Bouwes Bavinck JN, Harwood CA, Genders RE, Wisgerhof HC, Plasmeijer EI, Mitchell L, Olasz EB, Mosel DD, Pokorney MS, Serra AL, Feldmeyer L, Baumann Conzett K, Piaserico S, Belloni Fortina A, Jahn K, Geusau A, Gerritsen MJ, Seckin D, Gulec AT, Cetkovska P, Ricar J, Imko-Walczuk B, Proby CM, Hofbauer GF. Pain identifies squamous cell carcinoma in organ transplant recipients: the SCOPE-ITSCC PAIN study. Am J Transplant. 2014 Mar;14(3):668-76. Lambert, SR; Mladkova, N; Gulati, A; Hamoudi, R; Purdie, K; Cerio, R; Leigh, I; Proby, C; Harwood, CA; Key differences identified between actinic keratosis and cutaneous squamous cell carcinoma by transcriptome profiling; 2014 January 21; 110(2) 520-529. Se?kin D, Barete S, Euvrard S, Francès C, Kanitakis J, Geusau A, Del Marmol V, Harwood CA, Proby CM, Ali I, Güle? AT, Durukan E, Lebbé C, Alaibac M, Laffitte E, Cooper S, Bouwes Bavinck JN, Murphy GM, Ferrándiz C, M?rk C, Cetkovská P, Kempf W, Hofbauer GF. Primary cutaneous posttransplant lymphoproliferative disorders in solid organ transplant recipients: a multicenter European case series. Am J Transplant. 2013 Aug;13(8):2146-53. Matin RN, Chikh A, Law Pak Chong S, Mesher D, Graf M, Sanza P, Senatore V, Scatolini M, Moretti F, Leigh IM, Proby CM, Costanzo A, Chiorino G, Cerio R, Harwood CA, Bergamaschi D. p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis. J Exp Med. 2013 Mar 11;210(3):581-603. Nigro CL, Wang H, McHugh A, Lattanzio L, Matin R, Harwood C, Syed N, Hatzimichael E, Briasoulis E, Merlano M, Evans A, Thompson A, Leigh I, Fleming C, Inman GJ, Proby C, Crook T. Methylated Tissue Factor Pathway Inhibitor 2 (TFPI2) DNA in serum is a novel biomarker of metastatic melanoma. J Invest Dermatol. 2013 May;133(5):1278-85. Neale RE, Weissenborn S, Abeni D, Bouwes Bavinck JN, Euvrad S, Feltkamp MC, Green AC, Harwood CA, de Koning MN, Naldi L, Nindl I, Pawlita M, Proby C, Quint W, Waterboer T, Wieland U, Pfister HJ. Human Papillomavirus load in eyebrow hair follicles and risk of cutaneous squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):719-27. Hoogendijk-van den Akker JM, Harden PN, Hoitsma AJ, Proby CM, Wolterbeek R, Bouwes Bavinck JN, de Fijter JW. Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus. J Clin Oncol. 2013 Apr 1;31(10):1317-23. *Harwood CA, Mesher D, McGregor JM, Mitchell L, L-Green M, Raftery M, Cerio R, Leigh IM, Sasieni P, Proby CM. A surveillance model for skin cancer in organ transplant recipients: A 22-year prospective study in an ethnically diverse population. Am J Transplant. 2013 Jan;13(1):119-29. Verschooten L, Barrette K, Van Kelst S, Rubio Romero N, Proby C, de Vos R, Agostinis P, Garmyn M. Autophagy inhibit chloroquine enhanced the cell death inducing effect of the flavonoid Luteolin in metastatic squamous cell carcinoma cells. PLoS One 2012; 7(10): e48264 Epub 2012 Oct 26. *de Vries E, Trakatelli M, Kalabalikis D, Ferrandiz L, Ruiz-de-Casas A, Moreno-Ramirez D, Sotiriadis D, Ioannides D, Aquilina S, Apap C, Micallef R, Scerri L, Ulrich M, Pitk?nen S, Saksela O, Altsitsiadis E, Hinrichs B, Magnoni C, Fiorentini C, Majewski S, Ranki A, Stockfleth E, Proby C; EPIDERM Group. Known and potential risk factors for skin cancer in European populations: a multicentre case-control study. Br J Dermatol. 2012 Aug;167 Suppl 2:1-13. Flohil SC, Proby CM, Forrest AD, van Tiel S, Saksela O, Pitk?nen S, Ahti T, Micallef R, de Vries E; EPIDERM Group. Basal cell carcinomas without histological confirmation and their treatment: an audit in four European regions. Br J Dermatol. 2012 Aug;167 Suppl 2:22-8 Ferrandiz L, Ruiz-de-Casas A, Trakatelli M, de Vries E, Ulrich M, Aquilina S, Saksela O, Majewski S, Ranki A, Proby C, Magnoni C, Pitk?nen S, Kalokasidis K, Siskou S, Hinrichs B, Altsitsiadis E, Stockfleth E, Moreno-Ramirez D; EPIDERM Group. Assessing physicians’ preferences for skin cancer treatment in Europe. Br J Dermatol. 2012 Aug;167 Suppl 2:29-35. Traianou A, Ulrich M, Apalla Z, De Vries E, Bakirtzi K, Kalabalikis D, Ferrandiz L, Ruiz-de-Casas A, Moreno-Ramirez D, Sotiriadis D, Ioannides D, Aquilina S, Apap C, Micallef R, Scerri L, Pitk?nen S, Saksela O, Altsitsiadis E, Hinrichs B, Magnoni C, Fiorentini C, Majewski S, Ranki A, Proby CM, Stockfleth E, Trakatelli M; EPIDERM Group. Risk factors for actinic keratosis in eight European centres: a case-control study. Br J Dermatol. 2012 Aug;167 Suppl 2:36-42. Trakatelli M, Siskou S, Proby C, Tiplica GS, Hinrichs B, Altsitsiadis E, Kitsou A, Ferrandiz L, Aquilina S, Apap C, Ulrich M, Fiorentini C, Magnoni C, de Vries E, Flohil SC, Kalokasidis K, Moreno-Ramirez D, Ruiz-de-Casas A, Majewski S, Ranki A, Pitk?nen S, Saksela O, Ioannides D, Sotiriadis D, Stockfleth E; EPIDERM. The patient journey: a report of skin cancer care across Europe. Br J Dermatol. 2012;167 Suppl 2:43-52. Lo Nigro C, Monteverde M, Lee S, Lattanzio L, Vivenza D, Comino A, Syed N, McHugh A, Wang H, Proby C, Garrone O, Merlano M, Hatzimichael E, Briasoulis E, Gojis O, Palmieri C, Jordan L, Quinlan P, Thompson A, Crook T. NT5E CpG island methylation is a favourable breast cancer biomarker. Br J Cancer 2012 Jun26; 107(1): 75-83. Barrette K, Zutterman N, Van Kelst S, Proby C, Garmyn M. Pattern of sensitivity of progressive cutaneous squamous cell carcinoma cells to UVB and oxidative stress induced cell death. Photochem Photobiol Sci. 2013 Jan;12(1):104-10. Hack K, Reilly L, Proby C, Fleming C, Leigh I, Foerster J. Wnt5a inhibits the CpG oligodeoxynucleotide-triggered activation of human plasmacytoid dendritic cells. Clin Exp Dermatol 2012; 37(5): 557-61. Jian Li, Kai Wang, Fei Gao, Thomas D. Jensen, Shengting T. Li, Paula M. DeAngelis, Steen K?lvraa, Charlotte Proby, Ola Forslund, Lars Bolund and Ole Petter F. Clausen. Array Comparative Genomic Hybridization of Keratoacanthomas and Squamous Cell Carcinomas: Different Patterns of Genetic Aberrations Suggest Two Distinct Entities. J Invest Dermatol 2012 Aug; 132(8): 2060-6. doi: 10.1038/jid.2012.104. [Epub 2012 Apr 26]. Clayburgh DR, Gross ND, Proby CM, Koide J, Wong MH. The Effects of Epidermal Growth Factor Receptor and Insulin-like Growth Factor 1 Receptor inhibition on proliferation and intracellular signaling in cSCCHN: Potential for Dual Inhibition As a Therapeutic Modality. Head Neck. 2012 Apr 12. doi: 10.1002/hed.22936. [Epub ahead of print]. Wang H, Lee S, Nigro CL, Lattanzio L, Merlano M, Monteverde M, Matin R, Purdie K, Mladkova N, Bergamaschi D, Harwood C, Syed N, Szlosarek P, Briasoulis E, McHugh A, Thompson A, Evans A, Leigh I, Fleming C, Inman GJ, Hatzimichael E, Proby C, Crook T. NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity. Br J Cancer 2012; 106(8): 1446-52. de Vries E, Micallef R, Brewster DH, Gibbs JH, Flohil SC, Saksela O, Sankila R, Forrest AD, Trakatelli M, Coebergh JW, Proby CM; EPIDERM Group. Population-based estimates of the occurrence of multiple vs first primary basal cell carcinomas in 4 European regions. Arch Dermatolol 2012; 148(3): 347-54. Pourreyron C, Reilly L, Proby C, Panteleyev A, Fleming C, McLean K, South AP, Foerster J. Wnt5a is strongly expressed at the leading edge in non-melanoma skin cancer, forming active gradients, while canonical Wnt signalling is repressed. PLoS One 2012; 7(2): e31827. Lambert SR, Harwood CA, Purdie KJ, Gulati A, Matin RN, Romanowska M, Cerio R, Kelsell DP, Leigh IM, Proby CM. Metastatic cutaneous squamous cell carcinoma shows frequent deletion in the protein tyrosine phosphatase receptor type D gene. Int J Cancer. 2012 Aug 1;131(3):E216-26. doi: 10.1002/ijc.27333. Cheung BB, Koach J, Tan O, Kim P, Bell JL, D'andreti C, Sutton S, Malyukova A, Sekyere E, Norris M, Haber M, Kavallaris M, Cunningham AM, Proby CM, Leigh I, Wilmott JS, Cooper CL, Halliday GM, Scolyer RA, Marshall GM. The retinoid signaling molecule, TRIM16, is repressed during squamous cell carcinoma skin carcinogenesis in vivo and reduces skin cancer cell migration in vitro. J Pathol. 2012 Feb;226(3):451-62.